Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)
Johnson & Johnson (JNJ) posted Cash from Investing Activities of -$1.0 billion for Q1 2026, up 76.81% sequentially from -$4.5 billion in Q4 2025, and down 250.17% YoY from $692.6 million in Q1 2025.
Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Cash from Investing Activities data on file, last reported at -$1.0 billion in Q1 2026.
- Quarterly Cash from Investing Activities fell 250.17% year-over-year to -$1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.3 billion (down 32.0% YoY) and the FY2025 annual result came in at -$23.6 billion, down 26.82% from the prior year.
- Cash from Investing Activities rose to -$1.0 billion in Q1 2026 per JNJ's latest filing, from -$4.5 billion in the prior quarter.
- The five-year high for Cash from Investing Activities was $3.3 billion in Q2 2023, with the low at -$18.3 billion in Q2 2025.
- Average Cash from Investing Activities over 5 years is -$3.7 billion, with a median of -$1.3 billion recorded in 2024.
- Year-over-year, Cash from Investing Activities slumped 1864.32% in 2022 and soared 191.22% in 2023.
- Johnson & Johnson's Cash from Investing Activities stood at -$3.6 billion in 2022, then surged by 66.92% to -$1.2 billion in 2023, then slipped by 9.82% to -$1.3 billion in 2024, then slumped by 239.77% to -$4.5 billion in 2025, then soared by 76.81% to -$1.0 billion in 2026.
- Business Quant data shows JNJ's Cash from Investing Activities at -$1.0 billion in Q1 2026, -$4.5 billion in Q4 2025, and -$542.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -3.92 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -1.04 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -574.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.79 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -209.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -1.04 Bn |
| Mar 29, 2026 | -1.04 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Sep 28, 2025 | -542.00 Mn |
| Sep 28, 2025 | -542.00 Mn |
| Jun 29, 2025 | -18.26 Bn |
| Jun 29, 2025 | -18.26 Bn |
| Mar 30, 2025 | -297.00 Mn |
| Mar 30, 2025 | -297.00 Mn |
| Dec 29, 2024 | -1.32 Bn |
| Dec 29, 2024 | -1.32 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Mar 31, 2024 | -464.00 Mn |
| Mar 31, 2024 | -464.00 Mn |
| Dec 31, 2023 | -1.20 Bn |
| Dec 31, 2023 | -1.20 Bn |